Newsroom

Increasing Drug Prices Hurt Patients and Families

While it’s unconscionable that hedge fund pharmaceutical companies like Turing and Retrophin purchase treatments and suddenly raise prices, the current model in which drug companies raise prices year after year is just as bad for patients – and, frankly, unsustainable for our entire health care system.

Read more

American Academy of Neurology Joins Campaign for Sustainable Rx Pricing

Today the National Coalition on Health Care Action Fund announced that the American Academy of Neurology (AAN) has officially joined the coalition’s Campaign for Sustainable Rx Pricing. The American Academy of Neurology represents 30,000 members and is dedicated to promoting the highest quality patient-centered neurologic care.

Read more

Senate Special Committee on Aging Examines Drug Pricing

“Companies are buying decades-old prescription drugs and jacking up prices on vulnerable patients. It’s unconscionable. We need more transparency and competition in the prescription drug market to protect Americans from this appalling practice.”

Read more

FDA to Prioritize Generic Drug Applications

“Recently, the FDA took an important first step in acknowledging the need to introduce more competition by prioritizing generic applications where there is no competition. This effort will give patients better access to affordable treatments,” said John Rother, executive director of the Campaign for Sustainable Rx Pricing.

Read more